RSS

AKYNZEO

Swiss pharmaceutical group, Helsinn, and professional pharmaceutical subsidiary of CJ Group, CJ Healthcare, have announced that the oral formulation of AKYNZEO has been approved for use in Korea by the Korean Ministry of Food and Drug Safety (MFDS). Read more

News

Helsinn — a Swiss pharmaceutical group — and Glenmark Pharmaceuticals — a research-led global pharma company — have launched a fixed combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV), AKYNZEO, to the Indian market Read more

News

Swiss pharmaceutical group, Helsinn, has announced the launch of the intravenous formulation of AKYNZEO (a fixed combination of fosnetupitant, 235 mg, and palonosetron, 0.25 mg) in the US. Read more

News